Inmune Bio, Inc. (INMB): R&D Expense
$20.66M
Year ended 2025-12-31
+6.6%
3-year compound annual growth
+28.4%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $20.66M | -37.7% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $33.17M | +63.6% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $20.27M | +18.8% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $17.07M | -16.9% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $20.54M | +247.1% | 2023-03-02, From 2021-01-01 |
| 2020-12-31 | $5.92M | +80.3% | 2022-03-03, From 2020-01-01 |
| 2019-12-31 | $3.28M | -2.2% | 2021-03-04, From 2019-01-01 |
| 2018-12-31 | $3.35M | +670.6% | 2020-03-11, From 2018-01-01 |
| 2017-12-31 | $435.4K | n/a | 2019-03-29, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $20.66M | -37.7% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $6.00M | +33.5% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $3.92M | -36.7% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $37.59M | +9.4% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $4.19M | -16.6% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $3.13M | +127.7% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $60.22M | +10.8% |
| Creative Medical Technology Holdings, Inc. (CELZ) | 2025-12-31 | $2.26M | -5.9% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $35.33M | -4.1% |
Compare INMB, ENTX, AIM, SNTI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗